Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 9/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8897816 | 0.97 | SLC6A4 (0.50) | SLC6A4MAOATSHRCYP3A4MAPK1 | |
| SCHEMBL3781960 | 0.93 | TDP1 (0.50) | SLC6A4MAOATSHRCYP3A4MAPK1 | |
| SCHEMBL346860 | 0.86 | SLC6A4 (0.56) | SLC6A4MAOAMAPK1ALDH1A1NPC1 | |
| SCHEMBL8809913 | 0.80 | CA12 (0.57) | MAOATSHRCYP3A4MAPK1ALDH1A1 | |
| SCHEMBL12172517 | 0.78 | CYP3A4 (0.55) | TSHRCYP3A4MAPK1ALDH1A1MEN1 | |
| SCHEMBL8591154 | 0.78 | SLC6A4 (0.50) | SLC6A4MAOAMAPK1ALDH1A1MEN1 | |
| SCHEMBL1808815 | 0.78 | CYP3A4 (0.55) | MAOATSHRCYP3A4MAPK1ALDH1A1 | |
| SCHEMBL10316183 | 0.78 | SLC6A4 (0.50) | SLC6A4MAOATSHRCYP3A4MAPK1 | |
| SCHEMBL9793575 | 0.78 | SLC6A4 (0.50) | SLC6A4MAOANPC1RAB9A | |
| SCHEMBL3785538 | 0.77 | GCK (0.38) | SLC6A4MAOATSHRCYP3A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3396028-B1 | DIRECT ELECTROCHEMICAL SYNTHESIS OF DOPED CONDUCTIVE POLYMERS ON METAL ALLOYS | BOEING CO (US) | 2022-04-06 | — | — | EP | claimed |
| US-7211202-B2 | Process to make a conductive composition of a fluorinated polymer which contains polyaniline | ATOFINA (FR) | 2007-05-01 | — | — | US | claimed |
| EP-1428857-B1 | Process to make a conductive composition of a fluorinated polymer which contains polyaniline | ARKEMA FRANCE (FR) | 2007-01-31 | — | — | EP | claimed |
| CN-119490443-A | Photoresist main body material, preparation method thereof, photoresist composition containing photoresist main body material and photoresist coating | 中国科学院理化技术研究所 | 2025-02-21 | — | — | CN | disclosed |
| EP-4247797-A1 | 2-PHENYLBENZOTRIAZOL-5-AMINE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS (HBV) INFECTION | F. Hoffmann-La Roche AG (CH) | 2023-09-27 | — | — | EP | disclosed |
| US-11760775-B2 | Steroids and protein-conjugates thereof | REGENERON PHARMACEUTICALS, INC. | 2023-09-19 | — | — | US | disclosed |
| US-20230286927-A1 | 2-PHENYLBENZOTRIAZOL-5-AMINE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS (HBV) INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230286927-A1 | 2-PHENYLBENZOTRIAZOL-5-AMINE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS (HBV) INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230286927-A1 | 2-PHENYLBENZOTRIAZOL-5-AMINE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS (HBV) INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| WO-2022106588-A1 | 2-PHENYLBENZOTRIAZOL-5-AMINE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS (HBV) INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022106588-A1 | 2-PHENYLBENZOTRIAZOL-5-AMINE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS (HBV) INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2022-05-27 | — | — | WO | disclosed |
| US-5278213-A | Low viscosity solution | ALLIED SIGNAL INC. (US) | 1994-01-11 | — | — | US | disclosed |
| US-5019134-A | Triphenodioxazines | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-05-28 | — | — | US | disclosed |
| EP-0356014-A1 | Reactive Dyes | ZENECA LIMITED (GB) | 1990-02-28 | — | — | EP | disclosed |
| EP-0315862-A2 | Aromatically fluorinated fluoromethoxy- and fluoromethylthio-amino benzenes and their preparation | BAYER AG (DE) | 1989-05-17 | — | — | EP | disclosed |
| EP-0201811-A1 | 7-Oxabicycloheptane substituted aryl amino prostaglandin analogs and their use in inhibiting platelet aggregation and bronchoconstriction | E.R. Squibb & Sons, Inc. (US) | 1986-11-20 | — | — | EP | disclosed |
| US-4607048-A | 7-oxabicycloheptane substituted aryl amino prostaglandin analogs and their use in inhibiting platelet aggregation and bronchoconstriction | E. R. SQUIBB & SONS, INC. (US) | 1986-08-19 | — | — | US | disclosed |
| US-4303673-A | N-Propionylsarcosineanilides, process for their preparation, and pharmaceutical compositions containing them | A. NATTERMANN & CIE. GMBH (DE) | 1981-12-01 | — | — | US | disclosed |
| US-4150029-A | ANTIDEPRESSANTS | DELALANDE S.A. (FR) | 1979-04-17 | — | — | US | disclosed |
| US-4036849-A | ANTIMICROBIAL | AMERICAN CYANAMID COMPANY (US) | 1977-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286927-A1 | 2-PHENYLBENZOTRIAZOL-5-AMINE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS (HBV) INFECTION | HAVCR2, NR1H4, SLC10A1 | SLC6A4 2382/4885MAOA 707/4885TSHR 965/4885 |
| US-11760775-B2 | Steroids and protein-conjugates thereof | SERPINA6, NR3C1, NR3C2 | SLC6A4 3841/4885MAOA 4635/4885TSHR 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.